An interventional study of Indoor residual spray with Deltamethrin 2.5% WP in Dengue, sponsored by Pak Emirates Military Hospital. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Pak Emirates Military Hospital · Not applicable, Interventional, and Prevention
This quasi-experimental interventional study was conducted over 1 year, from May 2024-May 2025 at Station Health Organization, Combined Military Hospital, Peshawar Cantonment. Two comparable localities in Peshawar Cantonment were selected based on previous dengue incidence reports. Non-Probability consecutive sampling technique was used. Prior approval was sought from Station Commander, Station Headquarters Peshawar to conduct the study in Peshawar Cantonment. Hospital ethical review certificate was obtained (vide CMH Peshawar Letter No: 00254/25). Written informed consent was taken from the participants for inclusion in the study. One locality was designated as the intervention area (Indoor Residual Spray applied), and the other as the control area (Indoor Residual Spray not applied). Households were selected using a non-probability consecutive sampling technique.
In the intervention area, indoor residual spraying was conducted using Deltamethrin 2.5% WP, following WHO guidelines. Spray teams were trained and monitored to ensure proper application on interior walls, dark corners, and mosquito resting sites. Spraying was repeated every three months.
Entomological surveys were conducted at baseline and monthly thereafter in both areas, using larval/pupal indices (House Index and Breteau Index). Adult mosquito density was measured using backpack aspirators and resting catches. Dengue case data was collected by the Station Health Organization from CMH Peshawar and cross-checked with the Pathology department of the same hospital. The study was conducted as pilot study of the organization.
Data was analyzed using Statistical Pacakage for Social Sceinces version 27. Mean mosquito density, larval indices, and dengue incidence were compared between intervention and control areas using paired t-test. A p-value \< 0.05 was considered statistically significant.
283 studies on the registry are indexed under Dengue; 44 are open to participants now.
This study's enrollment of 200 is above the median of 132 across 197 interventional studies indexed under Dengue.
Browse Dengue studies →Pak Emirates Military Hospital is the lead sponsor of 24 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
100 households were inducted in the IRS Arms
Drug: Indoor residual spray with Deltamethrin 2.5% WP
100 households were inducted in the Control Arm
In the intervention area, indoor residual spraying was conducted using Deltamethrin 2.5% WP, following WHO guidelines. Spray teams were trained and monitored to ensure proper application on interior walls, dark corners, and mosquito resting sites. Spraying was repeated every three months.
To assess the safety of indoor residual spray in terms of participants reported adverse side effects after the use of spray ; both immediate and up to 3 months folllow up
To assess the safety of indoor residual spray in terms of participants reported adverse side effects after the use of spray ; both immediate and up to 3 months folllow up. Patients will report any adverse effects to the investigator, including rhinitis, skin rash, urticaria or any other newer finding noticed by the participant.
Time frame: 3 months follow up to asses the safety of indoor residual spray
To assess the efficacy of indoor residual spray using House Index
The Efficacy of indoor residual spray was assessed using House Index. House Index was compared for interventional area where the indoor residual spray was performed and the control area which was intervention naive. The baseline and 3 months follow up indices were compared to ascertain the efficacy of intervention. The House Index (HI) is the percentage of inspected houses that have mosquito larvae or pupae in or around them
Time frame: 3 months follow-up to assess the efficacy of indoor residual spray to kill the mosquitoes using changes in House Index.
The Efficacy of indoor residual spray was assessed using Bretau Index.
The Efficacy of indoor residual spray was assessed using Bretau Index. Bretau Index was compared for interventional area where the indoor residual spray was performed and the control area which was intervention naive. Bretau Index measures mosquito vector density by tracking the number of positive water-holding containers per 100 houses inspected
Time frame: The baseline and 3-month follow-up indices were compared to ascertain the efficacy of intervention.
Plan to share: Yes — Study protocol and statistical data analysis sheet/ methods will be shraed upon request
Supporting information: Study protocol, Statistical analysis plan
Time frame: 15 Sep 2026 to 15 Jun 2027
Access criteria: Upon request, any one associated with heathcare system may be able to accesss the study protocol and any statistical data analysis format
Ran from May 2024 to primary completion in May 2025, 12 months.
Of 25 non-industry interventional studies with no phase under Dengue, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 12 months is close to that.
Counting every sponsor, half of 30 studies reached it within 12 months; a quarter within 6 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pak Emirates Military Hospital